Related Experiment Video

Updated: Jul 24, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Decentralised, point-of-care CAR-T for multiple myeloma

Sébastien Anguille1, Laurens Krekelbergh1

  • 1Division of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium; Faculty of Medicine & Health Sciences, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium.

The Lancet. Oncology
|July 6, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

669

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K